Source: iQoncept / Shutterstock
The financial juggernaut AN2 Therapeutics (NASDAQ:ANTX) made waves with its latest financial disclosure for the fourth quarter of 2023.
- Defying expectations, AN2 Therapeutics delivered an earnings per share of -57 cents, soaring above analysts’ projections of -76 cents.
- Interestingly, the company chose to forgo revealing any revenue figures for the quarter.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/antx-stock-earnings-an2-therapeutics-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
